Rossana Cavallo

Rossana Cavallo

Auto-generated profile, based on publicly available information

Rossana Cavallo

Microbiology and Virology Unit, University Hospital City of Health and Science of Turin, 10126 Turin, Italy

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1987 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
GGGiovanni Gatti
Giovanni Gatti
RCRossana Cavallo
Rossana Cavallo
MSMaria Luisa Sartori
Maria Luisa Sartori
DPDaniela Del Ponte
Daniela Del Ponte
RMRosa Masera
Rosa Masera
AAAlberto Angeli
Alberto Angeli

25 August 2011 in Dermatology
Verified
Journal Article
Closed access
Pietro QuaglinoPietro Quaglino
Pietro Quaglino
MBM. Bergallo
M. Bergallo
RPR. Ponti
R. Ponti
EBE. Barberio
E. Barberio
SCS. Cicchelli
S. Cicchelli
MBM.G. Bernengo
M.G. Bernengo
Background: Psoriasis is sustained by pro-inflammatory CD4+ T helper cells mainly belonging to the Th1, Th17 and Th22 lineage. Objective: To identify whether treatment with the anti-tumour-necrosis-factor antagonist etanercept is able to induce significant modulations in transcription factor and cytokine mRNA gene expressions related to the different T cell immune response polarization (Th1, Th2, Th17 and regulatory T cells, Treg) and to correlate them with clinical response. Methods: The study population included 19 psoriasis patients treated with etanercept and 19 healthy subjects. Blood samples were collected at baseline and every 4 weeks during treatment. Taqman quantitative real-time polymerase chain reaction was applied to analyse the expression of: Stat-4, T-bet, IL-12p35 and IFN-γ (Th1-related); GATA-3, IL-4 (Th2-related); Stat-3, RORγt, IL-23p19 (Th17-related); Foxp3, IL-2 (Treg-related). Flow cytometry was applied to analyse CD4+CD25+brightFoxp3+ cells in peripheral blood. Results: Upregulation of Th1 and Th17 and downregulation of Treg subsets was found at baseline. The response to etanercept could be associated with a significant reversal of the Th1/Th17 activation, and a concomitant upregulation of Th2 and Treg subsets. Conclusion: Our data may contribute to a better understanding of the mechanisms underlying the achievement of clinical response in psoriasis and could be helpful for the identification of early predictive markers of response.

1 July 2007 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
ALAlessandro Lavagna
Alessandro Lavagna
MBMassimiliano Bergallo
Massimiliano Bergallo
MDMarco Daperno
Marco Daperno
RSRaffaello Sostegni
Raffaello Sostegni
CCCristina Costa
Cristina Costa
APAngelo Pera
Angelo Pera
Background. Infliximab is used for refractory Crohn's disease but there are concerns regarding long-term safety. Recently, JC-polyomavirus (JCV) was stu

30 December 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
RRRenato Romagnoli
Renato Romagnoli
Salvatore GruttadauriaSalvatore Gruttadauria
Salvatore Gruttadauria
GTGiuseppe Tisone
Giuseppe Tisone
GEGiuseppe Maria Ettorre
Giuseppe Maria Ettorre
LCLuciano De Carlis
Luciano De Carlis
PGPaolo Antonio Grossi
Paolo Antonio Grossi
COVID-19 pandemic dramatically impacted transplantation landscape. Scientific societies recommend against the use of donors with active SARS-CoV-2 infection. Italian Transplant Authority recommended to test recipients/donors for SARS-CoV-2-RNA immediately before liver transplant (LT) and, starting from November 2020, grafts from deceased donors with active SARS-CoV-2 infection were allowed to be considered for urgent-need transplant candidates with active/resolved COVID-19. We present the results of the first 10 LTs with active COVID-19 donors within an Italian multicenter series. Only two recipients had a positive molecular test at LT and one of them remained positive up to 21 days post-LT. None of the other eight recipients was found to be SARS-CoV-2 positive during follow-up. IgG against SARS-CoV-2 at LT were positive in 80% (8/10) of recipients, and 71% (5/7) showed neutralizing antibodies, expression of protective immunity related to recent COVID-19. In addition, testing for SARS-CoV-2 RNA on donors’ liver biopsy at transplantation was negative in 100% (9/9), suggesting a very low risk of transmission with LT. Immunosuppression regimen remained unchanged, according to standard protocol. Despite the small number of cases, these data suggest that transplanting livers from donors with active COVID-19 in informed candidates with SARS-CoV-2 immunity, might contribute to safely increase the donor pool.

1 April 2003 in Journal of Clinical Virology
Verified
Journal Article
Closed access
RCRossana Cavallo
Rossana Cavallo
CMC Merlino
C Merlino
DRD Re
D Re
CBC Bollero
C Bollero
MBM Bergallo
M Bergallo
APA.NEgro Ponzi
A.NEgro Ponzi

1 November 1993 in Virology
Verified
Journal Article
Closed access
Giorgio GribaudoGiorgio Gribaudo
Giorgio Gribaudo
SRStefania Ravaglia
Stefania Ravaglia
ACAndrea Caliendo
Andrea Caliendo
RCRossana Cavallo
Rossana Cavallo
Marisa GariglioMarisa Gariglio
Marisa Gariglio
SLSanto Landolfo
Santo Landolfo